Meet the Holmusk team at the 2024 Annual Congress of the Schizophrenia International Research Society, April 3 - 7, in Florence Italy.
2 posters will be co-presented by Boehringer Ingelheim and Holmusk, focused on the impact of cognitive impairment and negative symptoms in patients with schizophrenia. Boehringer Ingelheim leveraged Holmusk’s NeuroBlu Database, a longitudinal behavioral health real-world database containing de-identified, patient-level, clinical data, to conduct these analyses. Both analyses were performed in large and representative cohorts of patients with schizophrenia receiving mental healthcare. To learn more about the schizophrenia patient population in NeuroBlu, download our Schizophrenia Data Overview.
Authors: Kira Griffiths (Holmusk), Min Min Chan (Holmusk), Theresa Cassidy (Boehringer Ingelheim Pharmaceuticals) , Mayowa Oyesanya (Holmusk), Rifqi Alkhatib (Holmusk), Suzanne St Rose (Boehringer Ingelheim, Germany), Rashmi Patel (Institute of Psychiatry, Psychology, & Neuroscience, King’s College London)
Poster Presentation: F147
Date: April 5, 2024
Time: 12:30pm - 2:30pm
Location: Lunch and Poster Session II
This study analyzed real-world data from electronic health records (EHR) to investigate relationships between cognitive impairments / negative symptoms in schizophrenia and real-world clinical outcomes.
Title: Clinical characteristics of patients with cognitive impairment associated with schizophrenia
Authors: Theresa Cassidy (Boehringer Ingelheim Pharmaceuticals), Kira Griffiths (Holmusk), Min Min Chan (Holmusk), Mayowa Oyesanya (Holmusk), Rifqi Alkhatib (Holmusk), Suzanne St Rose (Boehringer Ingelheim, Germany), Rashmi Patel (Institute of Psychiatry, Psychology, & Neuroscience, King’s College London)
Poster Presentation: S152
Date: April 6, 2024
Time: 12pm - 2pm
Location: Lunch and Poster Session III
This study leveraged real-world data from electronic health records (EHR) to identify and characterize patients with schizophrenia with evidence of cognitive impairment.
Holmusk is committed to conducting rigorous behavioral and mental health research leveraging our proprietary NeuroBlu Database. NeuroBlu is a powerful analytics platform designed to explore the richest source of longitudinal behavioral health real-world data, containing both structured and unstructured patient-level clinical data sourced from de-identified electronic health records. Our collaboration with Boehringer Ingelheim represents a significant step forward in our joint mission to improve the lives of individuals affected by mental health disorders. Boehringer Ingelheim is leveraging real-word data in NeuroBlu to characterize patients with schizophrenia who experience symptoms for which there are minimal effective therapeutic inventions, with the goal to develop novel therapeutics for populations in need. By combining the expertise in pharmaceutical research and development with cutting-edge real-world evidence analytics, we have harnessed the power of data-driven insights to drive innovation in behavioral health.
Interested in learning more? Reach out to discuss how NeuroBlu can enhance your studies, drive better evidence, and improve patient outcomes in behavioral and mental health. Contact us to schedule a demo.
